181 related articles for article (PubMed ID: 1680552)
1. 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma.
Blount PL; Ramel S; Raskind WH; Haggitt RC; Sanchez CA; Dean PJ; Rabinovitch PS; Reid BJ
Cancer Res; 1991 Oct; 51(20):5482-6. PubMed ID: 1680552
[TBL] [Abstract][Full Text] [Related]
2. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy.
Blount PL; Galipeau PC; Sanchez CA; Neshat K; Levine DS; Yin J; Suzuki H; Abraham JM; Meltzer SJ; Reid BJ
Cancer Res; 1994 May; 54(9):2292-5. PubMed ID: 8162566
[TBL] [Abstract][Full Text] [Related]
3. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry.
Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H
Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405
[TBL] [Abstract][Full Text] [Related]
4. 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia.
Sanz-Ortega J; Hernández S; Saez MC; Sierra E; Sanz-Ortega G; Torres A; Balibrea JL; Sanz-Esponera J; Merino MJ
Hepatogastroenterology; 2003; 50(50):404-7. PubMed ID: 12749233
[TBL] [Abstract][Full Text] [Related]
5. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
[TBL] [Abstract][Full Text] [Related]
7. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.
Barrett MT; Sanchez CA; Galipeau PC; Neshat K; Emond M; Reid BJ
Oncogene; 1996 Nov; 13(9):1867-73. PubMed ID: 8934532
[TBL] [Abstract][Full Text] [Related]
8. Chromosomal instability in Barrett's esophagus is related to telomere shortening.
Finley JC; Reid BJ; Odze RD; Sanchez CA; Galipeau P; Li X; Self SG; Gollahon KA; Blount PL; Rabinovitch PS
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1451-7. PubMed ID: 16896031
[TBL] [Abstract][Full Text] [Related]
9. Progression to cancer in Barrett's esophagus is associated with genomic instability.
Rabinovitch PS; Reid BJ; Haggitt RC; Norwood TH; Rubin CE
Lab Invest; 1989 Jan; 60(1):65-71. PubMed ID: 2911184
[TBL] [Abstract][Full Text] [Related]
10. Barrett's oesophagus: microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence.
Gleeson CM; Sloan JM; McGuigan JA; Ritchie AJ; Weber JL; Russell SE
Genes Chromosomes Cancer; 1998 Jan; 21(1):49-60. PubMed ID: 9443041
[TBL] [Abstract][Full Text] [Related]
11. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma.
Gleeson CM; Sloan JM; McGuigan JA; Ritchie AJ; Russell SE
Cancer Res; 1995 Aug; 55(15):3406-11. PubMed ID: 7614480
[TBL] [Abstract][Full Text] [Related]
12. Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas.
Meltzer SJ; Yin J; Manin B; Rhyu MG; Cottrell J; Hudson E; Redd JL; Krasna MJ; Abraham JM; Reid BJ
Cancer Res; 1994 Jul; 54(13):3379-82. PubMed ID: 8012954
[TBL] [Abstract][Full Text] [Related]
13. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
14. p53-mutant clones and field effects in Barrett's esophagus.
Prevo LJ; Sanchez CA; Galipeau PC; Reid BJ
Cancer Res; 1999 Oct; 59(19):4784-7. PubMed ID: 10519384
[TBL] [Abstract][Full Text] [Related]
15. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
16. [Demonstration of clonal heterogeneity in adenocarcinomas on Barrett's esophagus by flow cytometric study of cellular DNA content].
Robaszkiewicz M; Volant A; Hardy E; Nousbaum JB; Calament G; Cauvin JM; Bail JP; Lozach P; Gouerou H
Gastroenterol Clin Biol; 1992; 16(6-7):540-6. PubMed ID: 1526415
[TBL] [Abstract][Full Text] [Related]
17. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
[TBL] [Abstract][Full Text] [Related]
18. Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma.
Barrett MT; Schutte M; Kern SE; Reid BJ
Cancer Res; 1996 Oct; 56(19):4351-3. PubMed ID: 8813122
[TBL] [Abstract][Full Text] [Related]
19. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas.
Michael D; Beer DG; Wilke CW; Miller DE; Glover TW
Oncogene; 1997 Oct; 15(14):1653-9. PubMed ID: 9349498
[TBL] [Abstract][Full Text] [Related]
20. Barrett's esophagus and esophageal adenocarcinoma.
Reid BJ
Gastroenterol Clin North Am; 1991 Dec; 20(4):817-34. PubMed ID: 1787015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
